MedTrace Logo

Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

NCT07240844 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-11-21

No results posted yet for this study

Summary

This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.

Conditions

  • Amyloid Cardiomyopathy

Interventions

DRUG

Placebo

Participants will receive placebo orally once daily for 12 weeks. The drug is administered in tablet form and is taken during the first or second treatment period of a crossover design.

DRUG

Enavogliflozin 0.3mg

Participants will receive Enavogliflozin 0.3 mg orally once daily for 12 weeks. The drug is administered in tablet form and is taken during the first or second treatment period of a crossover design.

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • Seoul St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Jong-Chan Youn, MD, PhD · Seoul St. Mary's Hospital, The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2027-04-29
Completion
2027-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07240844 on ClinicalTrials.gov